These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 22931519)

  • 21. Understanding the cardiovascular risk with non-insulin antidiabetic drugs.
    Athyros VG; Imprialos K; Stavropoulos K; Sahinidis A; Doumas M
    Expert Opin Drug Saf; 2019 Mar; 18(3):241-251. PubMed ID: 30810055
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Glucose-lowering drugs: balancing risks and benefits.
    The Lancet Diabetes Endocrinology
    Lancet Diabetes Endocrinol; 2017 Sep; 5(9):669. PubMed ID: 28802987
    [No Abstract]   [Full Text] [Related]  

  • 23. Letter: The UGDP study.
    Hubbard WM
    JAMA; 1975 Mar; 231(11):1133-4. PubMed ID: 1172807
    [No Abstract]   [Full Text] [Related]  

  • 24. PPAR-γ agonism for cardiovascular and renal protection.
    Sarafidis PA; Georgianos PI; Lasaridis AN
    Cardiovasc Ther; 2011 Dec; 29(6):377-84. PubMed ID: 20840193
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The clinical relevance of assessing advanced glycation endproducts accumulation in diabetes.
    Meerwaldt R; Links T; Zeebregts C; Tio R; Hillebrands JL; Smit A
    Cardiovasc Diabetol; 2008 Oct; 7():29. PubMed ID: 18840258
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Antidiabetic agents and vascular events.
    Keen H
    J Clin Pathol Suppl (R Coll Pathol); 1975; 9():99-105. PubMed ID: 783218
    [No Abstract]   [Full Text] [Related]  

  • 27. Influence of glycemic control on the development of diabetic cardiovascular and kidney disease.
    Saha SA; Tuttle KR
    Cardiol Clin; 2010 Aug; 28(3):497-516. PubMed ID: 20621253
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Editorial: Settling the UGDP controversy.
    Chalmers TC
    JAMA; 1975 Feb; 231(6):624-5. PubMed ID: 1172848
    [No Abstract]   [Full Text] [Related]  

  • 29. Clinical experience with glynclamide, a new hypoglycaemic agent.
    Burns FH
    Med J Aust; 1969 Aug; 2(9):436-9. PubMed ID: 4898056
    [No Abstract]   [Full Text] [Related]  

  • 30. [Anti-diabetic therapy and cardiovascular risk].
    Mannucci E
    G Ital Cardiol (Rome); 2014 Dec; 15(12 Suppl 2):3S. PubMed ID: 25623544
    [No Abstract]   [Full Text] [Related]  

  • 31. Assessment of cardiovascular risk of new drugs for the treatment of diabetes mellitus: risk assessment vs. risk aversion.
    Zannad F; Stough WG; Lipicky RJ; Tamargo J; Bakris GL; Borer JS; Alonso García Mde L; Hadjadj S; Koenig W; Kupfer S; McCullough PA; Mosenzon O; Pocock S; Scheen AJ; Sourij H; Van der Schueren B; Stahre C; White WB; Calvo G
    Eur Heart J Cardiovasc Pharmacother; 2016 Jul; 2(3):200-5. PubMed ID: 27418973
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Diabetes medications and cardiovascular outcome trials: Lessons learned.
    Patel KV; de Albuquerque Rocha N; McGuire DK
    Cleve Clin J Med; 2017 Oct; 84(10):759-767. PubMed ID: 28985176
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Intensive insulin therapy: results after ten years].
    Laube H
    Pharm Unserer Zeit; 2001 Jan; 30(1):40-5. PubMed ID: 11233182
    [No Abstract]   [Full Text] [Related]  

  • 34. Focus on metformin - a major cardiovascular medication. 'Diabesity - the biggest epidemic in human history'.
    Straughan JL
    Cardiovasc J Afr; 2007; 18(5):331-3. PubMed ID: 17985034
    [No Abstract]   [Full Text] [Related]  

  • 35. Misunderstanding or error? The UGDP report after four years.
    Marigo S; Adezati L; Burnetti P; Pozza G; Robba L; Urbinati G
    Acta Diabetol Lat; 1974; 11(5):357-422. PubMed ID: 4156992
    [No Abstract]   [Full Text] [Related]  

  • 36. [Oral anti-diabetics--dangerous drugs for diabetics?].
    Jervell J
    Tidsskr Nor Laegeforen; 1976 Aug; 96(22):1149. PubMed ID: 951694
    [No Abstract]   [Full Text] [Related]  

  • 37. [112th Scientific Meeting of the Japanese Society of Internal Medicine: Symposium: Emerging Comorbidities of Diabetes Mellitus: Drug Therapy of Diabetes Mellitus to Prevent Complications].
    Inagaki N
    Nihon Naika Gakkai Zasshi; 2015 Sep; 104(9):1912-6. PubMed ID: 30160897
    [No Abstract]   [Full Text] [Related]  

  • 38. Cardiovascular Protection with Anti-hyperglycemic Agents.
    Deedwania P; Acharya T
    Am J Cardiovasc Drugs; 2019 Jun; 19(3):249-257. PubMed ID: 30767126
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The age of randomized clinical trials: three important aspects of randomized clinical trials in cardiovascular pharmacotherapy with examples from lipid and diabetes trials.
    Drexel H; Rosano GMC; Lewis BS; Huber K; Vonbank A; Dopheide JF; Mader A; Niessner A; Savarese G; Wassmann S; Agewall S
    Eur Heart J Cardiovasc Pharmacother; 2020 Apr; 6(2):97-103. PubMed ID: 31298686
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Oral hypoglycaemic drugs and cardiovascular disease in maturity onset diabetes.
    Raheja BS
    Indian Heart J; 1979; 31(4):213-7. PubMed ID: 489037
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.